Metabolic & Weight Management

Pemvidutide

Also known as ALT-801

Emerging researchSubcutaneous injectionInvestigational; not approved by the FDA for any indication as of mid-2026. The FDA has granted pemvidutide Fast Track designation (for MASH and alcohol use disorder) and Breakthrough Therapy designation (for MASH, January 2026), but it remains in clinical development without marketing authorization. As a proprietary, patent-protected investigational agent owned by Altimmune, it is not a legitimate 503A/503B pharmacy-compounding product and is not legally available through compounding pharmacies. As a GLP-1/glucagon dual agonist, its GLP-1-agonist class is not currently prohibited by WADA; GLP-1 receptor agonists (e.g., semaglutide) have been on WADA's Monitoring Program since 2024 and remain on the 2026 Monitoring Program, meaning athlete use is being tracked in and out of competition but is not banned.

Pemvidutide (ALT-801) is a synthetic, single-molecule peptide developed by Altimmune that acts as a dual agonist with balanced activity at both the GLP-1 and glucagon receptors. The GLP-1 component is thought to reduce appetite, while the glucagon component is reported to increase energy expenditure and act directly on the liver to promote fatty-acid oxidation and reduce liver fat. It is engineered for once-weekly subcutaneous administration through an albumin-binding modification that extends its half-life. The research base consists of multiple Phase 2 and Phase 2b randomized, placebo-controlled human trials in obesity (MOMENTUM) and metabolic dysfunction-associated steatohepatitis (IMPACT), with Phase 2b MASH data published in The Lancet. Pemvidutide remains an investigational drug that has not received FDA marketing approval, though the FDA has granted it Fast Track and Breakthrough Therapy designations for MASH.

Studied / used for

Investigated for chronic weight management in obesity
Studied for metabolic dysfunction-associated steatohepatitis (MASH/NASH)
Studied for reduction of liver fat content in MASLD/fatty liver disease
Investigated for alcohol use disorder and alcohol-associated liver disease
Studied for effects on lipids, triglycerides, and blood pressure

Commonly reported side effects

Nausea (commonly reported, predominantly early and mild-to-moderate)
Vomiting (commonly reported upper-GI effect)
Diarrhea
Constipation

Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds